Les publications

Page en cours de mise à jour... Retrouvez ici les publications des équipes de recherche du CGO

375 publications
Année de publication :
Réseaux :

Anti-Glucosylsphingosine Autoimmunity, JAK2V617F-Dependent Interleukin-1β and JAK2V617F-Independent Cytokines in Myeloproliferative Neoplasms.

Inflammatory cytokines play a major role in myeloproliferative neoplasms (MPNs) as regulators of the MPN clone and as mediators of clinical symptoms and complications. Firstly, we investigated the effect of JAK2V617F on 42 molecules linked to inflammation.

  • Ref: doi: 10.3390/cancers12092446
  • Année de publication : 2020
  • Auteurs : Allain-Maillet S, Bosseboeuf A, Mennesson N, Bostoën M, Dufeu L, Choi EH, Cleyrat C, Mansier O, Lippert E, Le Bris Y, Gombert JM, Girodon F, Pettazzoni M, Bigot-Corbel E, Hermouet S
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

Analysis of the Targets and Glycosylation of Monoclonal IgAs From MGUS and Myeloma Patients.

Previous studies showed that monoclonal immunoglobulins G (IgGs) of “monoclonal gammopathy of undetermined significance” (MGUS) and myeloma were hyposialylated, thus presumably pro-inflammatory, and for about half of patients, the target of the monoclonal IgG was either a virus-Epstein…

  • Ref: doi: 10.3389/fimmu.2020.00854
  • Année de publication : 2020
  • Auteurs : Bosseboeuf A, Seillier C, Mennesson N, Allain-Maillet S, Fourny M, Tallet A, Piver E, Lehours P, Mégraud F, Berthelot L, Harb J, Bigot-Corbel E, Hermouet S
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with…

This study investigated the efficacy and safety of pimasertib (MEK1/MEK2 inhibitor) versus dacarbazine (DTIC) in patients with untreated NRAS-mutated melanoma.

  • Ref: doi: 10.3390/ijms21145025
  • Année de publication : 2020
  • Auteurs : Lebbé C, Dutriaux C, Lesimple T, Kruit W, Kerger J, Thomas L, Guillot B, Braud F, Garbe C, Grob JJ, Loquai C, Ferraresi V, Robert C, Vasey P, Conry R, Isaacs R, Espinosa E, Schueler A, Massimini G, Dréno B
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with…

We sought to identify patient subgroups with distinct postprogression overall survival (ppOS) outcomes and investigate the impact of original treatment assignment and initial postprogression treatment (ppRx) on ppOS.

  • Ref: doi: 10.1186/s12967-020-02458-x
  • Année de publication : 2020
  • Auteurs : Ascierto PA, Ribas A, Larkin J, McArthur GA, Lewis KD, Hauschild A, Flaherty KT, McKenna E, Zhu Q, Mun Y, Dréno B
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

Quantitative chimerism in CD3-negative mononuclear cells predicts prognosis in acute myeloid leukemia patients after hematopoietic stem…

Relapse is a major complication of acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (SCT). The objective of our study was to evaluate chimerism monitoring on the CD3-negative mononuclear cells by RQ-PCR to predict relapse of patients allografted for AML and to compare its performance with WT1 quantification.

  • Ref: doi: 10.3390/cancers12071727
  • Année de publication : 2020
  • Auteurs : Bouvier A, Riou J, Thépot S, Sutra Del Galy A, François S, Schmidt A, Orvain C, Estienne MH, Villate A, Luque Paz D, Cottin L, Ribourtout B, Beucher A, Delneste Y, Ifrah N, Ugo V, Hunault-Berger M, Blanchet O
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

Frequent Homozygous Deletions of Type I Interferon Genes in Pleural Mesothelioma Confer Sensitivity to Oncolytic Measles…

Oncolytic immunotherapy is based on the use of nonpathogenic replicative oncolytic viruses that infect and kill tumor cells exclusively. Recently, we found that the spontaneous oncolytic activity of the Schwarz strain of measles virus (MV) against human malignant pleural mesothelioma (MPM) depends on defects in the antiviral type I interferon (IFN-I) response in tumor cells.

  • Ref: doi: 10.1186/s12967-020-02458-x
  • Année de publication : 2020
  • Auteurs : Delaunay T, Achard C, Boisgerault N, Grard M, Petithomme T, Chatelain C, Dutoit S, Blanquart C, Royer PJ, Minvielle S, Quetel L, Meiller C, Jean D, Fradin D, Bennouna J, Magnan A, Cellerin L, Tangy F, Grégoire M, Fonteneau JF
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

A Functional Assay to Determine the Capacity of Oncolytic Viruses to Induce Immunogenic Tumor Cell Death.

Oncolytic immunotherapy efficacy relies partially on the induction of immunogenic tumor cell death following infection with oncolytic viruses (OV) to induce an antitumor immune response.

  • Ref: doi: 10.1007/978-1-4939-9794-7_8
  • Année de publication : 2020
  • Auteurs : Delaunay T, Achard C, Grégoire M, Tangy F, Boisgerault N, Fonteneau JF
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

Chemotherapy efficacy after first-line immunotherapy in 18 advanced melanoma patients.

n BRAF wild type advanced melanoma, immune checkpoint blockers such as anti-PD1 (anti-programmed cell death 1) are usually continued beyond progression for a hypothetical rare further response. Chemotherapy as a second-line option is considered ineffective by many practitioners based on historical data.

  • Ref: doi: 10.1097/MD.0000000000021329
  • Année de publication : 2020
  • Auteurs : Saint-Jean M, Fronteau C, Peuvrel L, Khammari A, Varey E, Quéreux G, Dréno B
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

Characteristics of MGUS and Multiple Myeloma According to the Target of Monoclonal Immunoglobulins, Glucosylsphingosine, or Epstein-Barr…

: Chronic stimulation by infectious or self-antigens initiates subsets of monoclonal gammopathies of undetermined significance (MGUS), smoldering multiple myeloma (SMM), or multiple myeloma (MM). Recently, glucosylsphingosine (GlcSph) was reported to be the target of one third of monoclonal immunoglobulins (Igs).

  • Ref: doi: 10.3390/cancers12051254
  • Année de publication : 2020
  • Auteurs : Bosseboeuf A, Mennesson N, Allain-Maillet S, Tallet A, Piver E, Decaux O, Moreau C, Moreau P, Lehours P, Mégraud F, Salle V, Bigot-Corbel E, Harb J, Hermouet S
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication